FindTrial
Sign In

Administration study as a part of research toward the influence of growth hormone releasing peptide GHRP-2 on detection of rhGH

Administration study as a part of research toward the influence of growth hormone releasing peptide GHRP-2 on detection of rhGH

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220995
Enrollment
15
Registered
2010-02-05
Start date
2010-02-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : GHRP-2 INN of investigational material : Therapeutic category code : 729 Other diagnostic agents (except extracorporeal diagnostic medicines) Dosage and
) was subcutaneous administered during fasting healthy male volunteers.

Sponsors

Mitsubishi chemical Medience Corporation
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Weight: more than 50 kg and under 66kg BMI: more than 18.5 and under 25

Exclusion criteria

Exclusion criteria: Hypersensitive to drugs, A hystory of alcoholism of drug addiction, Ethical or OTC pharmaceuticals administration within two before scheduled administration of the study, Supplement, grapefruit or its products, or foods containing Hyperrium perforatum consumed within one week before scheduled administration of the study. Not less than 200 ml of blood is collected within 30 days or not less than 400 ml of blood is collected within 90 days before scheduled administration of the study.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026